Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vardenafil
Drug ID BADD_D02335
Description Vardenafil (Levitra) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
Indications and Usage Used for the treatment of erectile dysfunction
Marketing Status Prescription; Discontinued
ATC Code G04BE09
DrugBank ID DB00862
KEGG ID D08668
MeSH ID D000069058
PubChem ID 135400189
TTD Drug ID D0C9SY
NDC Product Code 46708-235; 51407-174; 33342-203; 71610-477; 47621-303; 70710-1071; 70771-1050; 70771-1047; 70771-1049; 70710-1069; 70710-1070; 62332-235; 70710-1068; 70771-1048
Synonyms Vardenafil Dihydrochloride | Dihydrochloride, Vardenafil | Vardenafil Hydrochloride Anhydrous | Anhydrous, Vardenafil Hydrochloride | Hydrochloride Anhydrous, Vardenafil | Vardenafil | 1-(((3-(3,4-dihydro-5-methyl)-4-oxo-7-propylimidazo(5,1-f)-as-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine | Levitra | Vardenafil Hydrochloride Trihydrate | Hydrochloride Trihydrate, Vardenafil | Trihydrate, Vardenafil Hydrochloride | Vardenafil Hydrochloride | Hydrochloride, Vardenafil
Chemical Information
Molecular Formula C23H32N6O4S
CAS Registry Number 224785-90-4
SMILES CCCC1=NC(=C2N1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.001652%
Abnormal sensation in eye06.01.01.001--Not Available
Accommodation disorder06.02.04.001--Not Available
Alanine aminotransferase increased13.03.01.003--
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angina unstable24.04.04.004; 02.02.02.004--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.0010.001652%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.0050.002479%
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness transient06.02.02.002; 17.17.01.004--Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.0010.000431%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000431%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.001652%Not Available
Chromatopsia06.02.05.001--Not Available
Colour blindness acquired06.02.09.002--Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages